# SENATE BILL No. 43

# By Committee on Public Health and Welfare

1-18

AN ACT making and concerning appropriations for the fiscal years ending June 30, 2023, June 30, 2024, and June 30, 2025, for the university of Kansas medical center; relating to conducting certain clinical trials at the midwest stem cell therapy center.

1 2

Be it enacted by the Legislature of the State of Kansas: Section 1.

ion 1.

# UNIVERSITY OF KANSAS MEDICAL CENTER

(a) There is appropriated for the above agency from the state general fund for the fiscal year ending June 30, 2023, the following:

Midwest stem cell therapy center (683-00-1000-0800)................\$500,000 *Provided,* That expenditures may be made from the midwest stem cell therapy center account in an amount not to exceed \$500,000 for the purpose of conducting clinical trials to treat patients with COVID-19 and other respiratory diseases using MSCTC-0010 cells developed at the midwest stem cell therapy center: *Provided further,* That such expenditures shall be made solely under the direction and control of the director of the midwest stem cell therapy center.

Sec. 2.

#### UNIVERSITY OF KANSAS MEDICAL CENTER

(a) Any unencumbered balance in the midwest stem cell therapy center account (683-00-1000-0800) in excess of \$100 as of June 30, 2023, is hereby reappropriated for fiscal year 2024: *Provided,* That during the fiscal year ending June 30, 2024, expenditures may be made from the midwest stem cell therapy account in an amount not to exceed \$500,000 for the purpose of conducting clinical trials to treat patients with COVID-19 and other respiratory diseases using MSCTC-0010 cells developed at the midwest stem cell therapy center: *Provided further,* That such expenditures shall be made solely under the direction and control of the director of the midwest stem cell therapy center.

Sec. 3.

#### UNIVERSITY OF KANSAS MEDICAL CENTER

(a) Any unencumbered balance in the midwest stem cell therapy center account (683-00-1000-0800) in excess of \$100 as of June 30, 2024, is hereby reappropriated for fiscal year 2025: *Provided*, That during the fiscal year ending June 30, 2025, expenditures may be made from the

SB 43 2

7

midwest stem cell therapy account in an amount not to exceed \$500,000
for the purpose of conducting clinical trials to treat patients with COVID19 and other respiratory diseases using MSCTC-0010 cells developed at
the midwest stem cell therapy center: *Provided further*, That such
expenditures shall be made solely under the direction and control of the
director of the midwest stem cell therapy center.

Sec. 4. This act shall take effect and be in force from and after its publication in the Kansas register.